Outcome of Antidepressants Treatment among Adult Patients in KSA: A Cross-Sectional Study
DOI:
https://doi.org/10.63278/10.63278/mme.v31.1Abstract
Objective: This research aims to determine the Outcome of Antidepressants Treatment among Adult Patients in KSA.
Methods: This study will employ a cross-sectional design to assess the outcomes of antidepressant treatment among adult patients diagnosed with depression in Saudi Arabia. This design will allow for data collection at a single point in time, facilitating the examination of treatment effectiveness and related factors. The sample size undertaken for the study was 680 in order to understand better the factors responsible.
Results: The study included 680 participants. The most frequent age among them was 34-41 years (n= 198, 29.1%%) followed by 26-33 years (n= 183, 26.9%), then 42-49 years (n=137, 20.1%), 50 and more years (n=126, 18.5%), finally age from 18-25 years (n=36, 5.3%). The most frequent gender among study participants was male (n= 397, 58%) and female (n= 283, 42%). Study participants' most frequent marital status was married (n= 475, 69.9%), followed by single (n= 151, 22.2%), then divorce (n=36, 5.3%), and widow (n=18, 2.6%). The participants were asked if they smoked, and the majority's responses were no (n=587, 86%) and yes (n=93, 14%). Depression duration among study participants, with most of them not diagnosed with depression (n= 587, 45.9%) and depression duration (n= 93, 14%). The participants who were diagnosed with depression were asked if they stopped taking antidepressant medications when they felt better, and the majority's responses were no (n=61, 65.6%) and yes (n=32, 4.7%). The participants who were diagnosed with depression were asked if they stopped taking medications when they felt worse after taking them, and the majority's responses were no (n=70, 10.3%) and yes (n=23, 3.4%).
Conclusion: The findings of this study highlight critical aspects of antidepressant treatment outcomes among adults in Saudi Arabia. Despite the established effectiveness of antidepressant medications, adherence remains a significant challenge, with notable percentages of participants reporting discontinuation of medications both when feeling better and worse. Sociodemographic factors, such as age, gender, and marital status, play a role in shaping treatment patterns, but they do not fully account for variations in adherence. Additionally, the results underscore the importance of addressing subjective factors, such as patients' beliefs about medication efficacy and side effects, significantly impacting adherence rates.
References
Osterberg L, Blaschke T. Adherence to medication. New Engl J Med. 2005;353(5):487–497.
Burkhart PV, Sabaté E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35(3):207.
Unni EJ, Farris KB. Unintentional non-adherence and belief in medicines in older adults. Patient Educ Couns. 2011;83(2):265–268.
Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851–858.
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498–1504.
Rivero-Santana A, Perestelo-Perez L, Pérez-Ramos J, Serrano-Aguilar P, De Las Cuevas C. Sociodemographic and clinical predictors of compliance with antidepressants for depressive disorders: systematic review of observational studies. Patient Prefer Adherence. 2013;7:151–169.
Al-Khathami AD, Ogbeide DO. Prevalence of mental illness among Saudi adult primary-care patients in Central Saudi Arabia. Saudi Med J. 2002;23(6):721–724.
Dijkstra A, Jaspers M, van Zwieten M. Psychiatric and psychological factors in patient decision making concerning antidepressant use. J Consult Clin Psychol. 2008;76(1):149–157.
Hansen HV, Kessing LV. Adherence to antidepressant treatment. Expert Rev Neurother. 2007;7(1):57–62.
Katon W, Von Korff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care. 1992;30(1):67–76.
Keller MB. The long-term treatment of depression. J Clin Psychiat. 1998;60:41–45.
Bulloch AG, Patten SB. Non-adherence with psychotropic medications in the general population. Soc Psychiatry Psychiatr Epidemiol. 2010;45(1):47–56.
Al-Qasem A, Smith F, Clifford S. Adherence to medication among chronic patients in Middle Eastern countries: review of studies. East Mediterr Health J. 2011;17(4):356–363.
Al-Saffar N, Deshmukh A, Carter P, Adib S. Effect of information leaflets and counselling on antidepressant adherence: open randomised controlled trial in a psychiatric hospital in Kuwait. Int J Pharm Pract. 2005;13(2):123–131.
Al-Jumah KA, Qureshi NA. Impact of pharmacist interventions on patients’ adherence to antidepressants and patient-reported outcomes: a systematic review. Patient Prefer Adherence. 2011;6:87–100.
Alhulwah LM, Alhathloul AM, Alblowi AS, Alyahya KM. Long term antidepressants prescribing in the Psychiatry Department at Riyadh Military Hospital. Saudi Med J. 2011;32(10):1051–1054.
Tourkmani AM, Al Khashan HI, Albabtain MA, Al Harbi TJ, Al Qahatani HB, Bakhiet AH. Medication adherence among patients in a chronic disease clinic. Saudi Med J. 2012;33(12):1278–1284.
Alhewiti A. Adherence to long-term therapies and beliefs about medications. Int J Family Med. 2014;2014:479596.
Banerjee S, Varma RP. Factors affecting non-adherence among patients diagnosed with unipolar depression in a psychiatric department of a tertiary hospital in Kolkata, India. Depress Res Treat. 2013;2013:809542.
Tamburrino MB, Nagel RW, Chahal MK, Lynch DJ. Antidepressant medication adherence: a study of primary care patients. Prim Care Companion J Clin Psychiatry. 2009;11(5):205–211.
Hunot VM, Horne R, Leese MN, Churchill RC. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry. 2007;9(2):91–99.
Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the Necessity–Concerns Framework. J Psychosom Res. 2008;64(1):41–46.
Horne R, Graupner L, Frost S, Weinman J, Wright SM, Hankins M. Medicine in a multi-cultural society: the effect of cultural background on beliefs about medications. Social Sci Med. 2004;59(6):1307–1313.
World Health Organization . Geneva: 2017. Depression and Other Common Mental Disorders: Global Health Estimates.
Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.
American Psychiatric Association What Is Depression? Available from https://www.psychiatry.org/patients-families/depression/what-is-depression. [Last accessed on 2024 Sep 21].
National Institute of Mental Health (NIMH) Major Depression. 2017 Available from: https://www.nimh.nih.gov/health/statistics/major-depression.shtml. [Last accessed on 2024 Sep 21].
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163:1905–17.
Alsoghair MI, Alharbi AS, Aldekhail AI, Alharbi YO, Alkhuzayyim FA, Alowais AF, et al. Prevalence of depression and anxiety among Qassim University students during the COVID-19 pandemic. Cureus. 2023;15:e34866.
Peterson CJ, Sarangi A, Bangash F. Neurological sequelae of COVID-19: A review. Egypt J Neurol Psychiatr Neurosurg. 2021;57:122.
Wright K, Sarangi A, Ibrahim Y. The psychiatric effects of COVID-19 thus far: A review of the current literature. Southwest Respir Crit Care Chron. 2020;8:17–28.
Alamri HS, Algarni A, Shehata SF, Al Bshabshe A, Alshehri NN, ALAsiri AM, et al. Prevalence of depression, anxiety, and stress among the general population in Saudi Arabia during Covid-19 pandemic. Int J Environ Res Public Health. 2020;17:9183.
Bschor T. Therapy-resistant depression. Expert Rev Neurother. 2010;10:77–86.
European Medicines Agency (EMA) Guideline on clinical investigation of medicinal products in the treatment of depression. EMA/CHMP/185423/2010 Rev.
Al-Harbi KS. Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–88.
Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66(Suppl 8):5–12.
Döme P, Kunovszki P, Takács P, Fehér L, Balázs T, Dede K, et al. Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis. PLoS One. 2021;16:e0245510.
Gałecki P, Samochowiec J, Mikułowska M, Szulc A. Treatment-resistant depression in Poland-epidemiology and treatment. J Clin Med. 2022;11:480.
Kim N, Cho SJ, Kim H, Kim SH, Lee HJ, Park CHK, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea. PLoS One. 2019;14:e0221552.
Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10–7.
Yuan-Pang Wang. Clarice Gorenstein. The Beck depression inventory: Uses and applications The Neuroscience of Depression. 2021 Available at https://www.sciencedirect.com/topics/neuroscience/beck-depression-inventory. [Last accessed on 2024 Sep 21].
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2024 Suhail Abdalhameed Abdalrasheed Khan, Hoda Jeahad Abousada, Elham Mohammed Saleh AlBediny, Mohammed Bandar Alharbi, Shakir Abdullateef Darji, Shaima Nabeel Khodhari, Bayan Juman Alghamdi, Rana Mohammed Badighaish, Rojina Majed Aftab, Ghadi Osama Khayyat, Ahmed Yahya Haqawi, Majed Hassan Mathkur, Renad Mehsen Solan, Norah Ibrahim Asiri, Omar Sukayk Alamri
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their published articles online (e.g., in institutional repositories or on their website, social networks like ResearchGate or Academia), as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Except where otherwise noted, the content on this site is licensed under a Creative Commons Attribution 4.0 International License.
According to the 